



Contribution ID: 34

Type: **Talk**

## New insight into the physiological activities of Amyloid Beta monomers

Wednesday, 6 October 2021 11:15 (15 minutes)

Alzheimer's disease (AD) is one of the most common form of dementia in the elderly, characterized by a progressive neurodegeneration associated with synaptic dysfunction, pathological accumulation of  $\beta$ -amyloid (A $\beta$ ) in plaques, and neuronal loss. The self-association of A $\beta$  monomers into soluble oligomers seems to be crucial for the development of neurotoxicity (Walsh and Selkoe, 2007).

Some of the toxic effects of A $\beta$  are mediated by its adverse effect on neurotrophic factor expressions. In particular, A $\beta$  oligomers have been found to decrease both phosphorylated CREB and BDNF mRNA in the neuroblastoma cell line, SH-SY5Y, suggesting that oligomeric A $\beta$  could compromise neuronal functions in AD by downregulating BDNF (Garzon and Fahnstock, 2007). Accordingly, phosphorylated CREB and CREB-regulated BDNF are recently shown to be reduced in the brain of AD patients and Tg2576 mice (Pugazhenthii, 2011)

We previously reported a neuroprotective activity of monomeric A $\beta$  involving the activation of a PI3K/Akt survival pathway (Giuffrida et al., 2009). Here we demonstrate that A $\beta$  monomers are specifically able to activate CREB, a converging point for mechanisms and pathways involved in memory formation (Teich et al., 2015). Our data suggest a new model whereby A $\beta$  monomers may preserve cognitive decline.

### References:

1. Walsh DM, Selkoe DJ., J. Neurochem., 2007, 101, 1172–1184.
2. Garzon DJ, Fahnstock M. J., Neurosci., 2007, 27, 2628-2635.
3. Pugazhenthii S., et al., Mol. Neurodegener. 2011, 6,60.
4. Giuffrida ML., Caraci F. et al., J. Neurosci. 2009, 29, 10582-10587.
5. Teich AF., Nicholls RE. et al., Neurotherapeutics, 2015, 12, 29-41.

### Acknowledgements:

We acknowledge financial support from MIUR, grant SIR RBS1148TJD to M.L. Giuffrida. S.Zimbone is supported by a SIR project post-doctoral contract.

**Primary authors:** Dr ZIMBONE, Stefania (CNR - Istituto di Cristallografia); Dr MONACO, Irene (CNR - Istituto di Cristallografia); Dr GIANÌ, Fiorenza (Endocrinology, Department of Clinical and Experimental Medicine); Prof. PANDINI, Giuseppe (Endocrinology, Department of Clinical and Experimental Medicine); Dr COPANI, Agata (Department of Drug Sciences, University of Catania); Dr GIUFFRIDA, Maria Laura (CNR - Istituto di Cristallografia); Dr RIZZARELLI, Enrico (CNR - Istituto di Cristallografia)

**Presenter:** Dr ZIMBONE, Stefania (CNR - Istituto di Cristallografia)

**Session Classification:** Session